TEDA Nucleic Acid Medicine Industrial Park Inaugurated with Multiple Major Projects Landing in TEDA

On September 17, the 9th China (Tianjin) Nucleic Acid Drug Conference was held in TEDA. The conference focused on the latest developments and trends in multiple fields, establishing a cooperative exchange platform integrating insiders involving industry, academia, research, application, regulation, and investment, and opening a new chapter in nucleic acid drugs empowering human health.

“One Park, One Center” Officially Inaugurated

During the conference, the TEDA Nucleic Acid Medicine Industrial Park was officially inaugurated. Located in TEDA West, the park covers approximately 2.3 million square meters and is planned with multiple projects in collaboration. It currently includes the CanSino International Vaccine Industrial Park, a series projects of Asymchem in high-end formulation pilot and industrialization, industrial projects and supporting schools such as Azemidite, Pharmaron, JenKem, Agela-Phenomenex, and Tianjin Vocational College of Bioengineering, as well as new projects like the Boyun High-Performance Chromatography Consumables Production Project in the eastern expansion area.

The Tianjin Nucleic Acid Industry Innovation Service Center was simultaneously inaugurated. As a professional institution integrating the management, operation, and technical services of the entire nucleic acid drug industry chain, it will focus on the core needs of the TEDA Nucleic Acid Medicine Industrial Park and serve as a key support platform for promoting the upgrade of the regional nucleic acid medicine industry.

Multiple Major Projects Signed and Landed

At the conference, three key projects were signed on-site, covering areas such as the construction of a global R&D innovation and manufacturing base, the development of novel nucleic acid drugs and vaccines, and the research of nucleic acid drugs for coronary heart organoids.

Among them, the Danaher Global R&D Innovation and Manufacturing Base project, invested approximately 100 million yuan by Agela-Phenomenex, a brand under the life science platform of the Fortune 500 Danaher Group, will focus on global R&D and manufacturing of chromatography consumables. This will effectively drive local high-end talent employment and further enhance the supporting industrial chain of TEDA’s small nucleic acid sector.

CanSinoBIO and Tianjin Quanhecheng Technology Co., Ltd. signed a strategic cooperation framework agreement. The two key enterprises in the nucleic acid drug industry chain will jointly implement innovative design of novel nucleic acid drugs and vaccines, as well as independently intellectual-property-protected nucleic acid delivery systems, to promote industrial development and upgrading.

The State Key Laboratory of Medicinal Chemical Biology, together with Tianjin International Joint Institute of Biomedicine, YUGEN (Tianjin) Medical Technology Co., Ltd., and Tianjin Clin-nov Medical Technology Development Co., Ltd., signed an agreement on the project of accelerating nucleic acid drug development using coronary heart organoids. The four parties will leverage their respective strengths to accelerate the development and efficacy screening of nucleic acid drugs for heart disease treatment, realizing a new model of personalized customized healthcare.

The nucleic acid pharmaceutical industry is one of the core sectors being prioritized for development in TEDA. Currently, the zone has established a comprehensive nucleic acid drug industry chain covering key segments such as nucleic acid raw materials and active pharmaceutical ingredients (APIs), nucleic acid vaccines, synthesis equipment, purification devices and fillers, nucleic acid drug delivery carriers, nucleic acid formulations, and related technical services. More than 40 supporting enterprises operate within the ecosystem.